Clinical trial · Observational
Detection of Genetic Markers of Lung Cancer
Detection of Genetic Markers of Lung Cancer Initiation and Progression
NCT00280202CI-TRIAL-00096771recruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this research study is to determine the genetic changes and immunologic changes that are involved in the development and progression of bronchogenic lung cancer.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Lung Cancer | Malignant Lung Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (6)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Analysis of lymph nodes | Procedure | — | UNRESOLVED |
| Biopsy of abnormal & suspicious areas of the bronchial tree | Procedure | — | UNRESOLVED |
| Biopsy of the major carinal area | Procedure | — | UNRESOLVED |
| Bronchoalveolar Lavage (BAL) for cytokine analysis | Procedure | — | UNRESOLVED |
| Correlation of flow cytometric & RT PCR for TNM stage | Procedure | — | UNRESOLVED |
| Evaluation of the tumor for DNA mutations | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- The odds ratio for the risk of lung cancer associated with molecular markers
- timeFrame
- No specific time frame
Secondary outcomes (10)
- measure
- To obtain/maintain in cell culture "normal" bronchial epithelial cells(NBECs), tumors, and organoids from subjects undergoing resection for treatment of lung carcinoma and mesothelioma.
- timeFrame
- No specific time frame
- measure
- To harvest NBEC and lung tumors for evaluation of genetic abnormalities; this will be obtained at the time of bronchoscopy and lung resection.
- timeFrame
- No specific time frame
- measure
- To perform molecular analysis including PCR amplification, flow cytometry, immunohistochemistry, and gene analysis from NBECs, tumors, adjacent & normal lung, and blood.
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Histologic confirmation of lung cancer, lung metastases from a primary site other than lung, mesothelioma or a radiographic lesion highly suspicious for malignancy * Written informed consent. * To be scheduled for a biopsy or surgical resection or have already had a biopsy and/or surgical removal of a lung mass Exclusion Criteria: None
References
Publications (0)
Data not yet available
No reference posted for this study.